266 related articles for article (PubMed ID: 9697990)
1. Blood levels of transforming growth factor-beta 1 (TGF-beta1) are elevated in both relapsing remitting and chronic progressive multiple sclerosis (MS) patients and are further augmented by treatment with interferon-beta 1b (IFN-beta1b).
Nicoletti F; Di Marco R; Patti F; Reggio E; Nicoletti A; Zaccone P; Stivala F; Meroni PL; Reggio A
Clin Exp Immunol; 1998 Jul; 113(1):96-9. PubMed ID: 9697990
[TBL] [Abstract][Full Text] [Related]
2. Immunomodulatory effects of interferon-beta-1b in patients with multiple sclerosis.
Ossege LM; Sindern E; Patzold T; Malin JP
Int Immunopharmacol; 2001 Jun; 1(6):1085-100. PubMed ID: 11407304
[TBL] [Abstract][Full Text] [Related]
3. In vivo effect of interferon-beta 1a on interleukin-12 and TGF-beta(1) cytokines in patients with relapsing-remitting multiple sclerosis.
Losy J; Michałowska-Wender G
Acta Neurol Scand; 2002 Jul; 106(1):44-6. PubMed ID: 12067328
[TBL] [Abstract][Full Text] [Related]
4. Urinary myelin basic protein-like material in patients with multiple sclerosis during interferon beta-1b treatment.
Whitaker JN; Layton BA; Bartolucci AA; Mitchell GW; Bashir K; Goodwin J; Kachelhofer RD
Arch Neurol; 1999 Jun; 56(6):687-91. PubMed ID: 10369307
[TBL] [Abstract][Full Text] [Related]
5. Downregulation of transforming growth factor-beta1 in interferon-beta1a-treated MS patients.
Lünemann JD; Aktas O; Gniadek P; Zschenderlein R; Zipp F
Neurology; 2001 Sep; 57(6):1132-4. PubMed ID: 11571354
[TBL] [Abstract][Full Text] [Related]
6. Further study on the specificity and incidence of neutralizing antibodies to interferon (IFN) in relapsing remitting multiple sclerosis patients treated with IFN beta-1a or IFN beta-1b.
Antonelli G; Simeoni E; Bagnato F; Pozzilli C; Turriziani O; Tesoro R; Di Marco P; Gasperini C; Fieschi C; Dianzani F
J Neurol Sci; 1999 Oct; 168(2):131-6. PubMed ID: 10526196
[TBL] [Abstract][Full Text] [Related]
7. Effect of 1-year treatment with interferon-beta1b on thyroid function and autoimmunity in patients with multiple sclerosis.
Monzani F; Caraccio N; Meucci G; Lombardo F; Moscato G; Casolaro A; Ferdeghini M; Murri L; Ferrannini E
Eur J Endocrinol; 1999 Oct; 141(4):325-31. PubMed ID: 10526243
[TBL] [Abstract][Full Text] [Related]
8. Interferon-beta1b for the treatment of multiple sclerosis.
Lam S; Wang S; Gottesman M
Expert Opin Drug Metab Toxicol; 2008 Aug; 4(8):1111-7. PubMed ID: 18680445
[TBL] [Abstract][Full Text] [Related]
9. Autoantibodies in multiple sclerosis patients before and during IFN-beta 1b treatment: are they correlated with the occurrence of autoimmune diseases?
Verdun E; Isoardo G; Oggero A; Ferrero B; Ghezzi A; Montanari E; Zaffaroni M; Durelli L;
J Interferon Cytokine Res; 2002 Feb; 22(2):245-55. PubMed ID: 11911808
[TBL] [Abstract][Full Text] [Related]
10. Effects of interferon and glatiramer acetate on cytokine patterns in multiple sclerosis patients.
Ganji A; Monfared ME; Shapoori S; Nourbakhsh P; Ghazavi A; Ghasami K; Mosayebi G
Cytokine; 2020 Feb; 126():154911. PubMed ID: 31731047
[TBL] [Abstract][Full Text] [Related]
11. Newer versus older treatments for relapsing-remitting multiple sclerosis.
Weinstock-Guttman B; Cohen JA
Drug Saf; 1996 Feb; 14(2):121-30. PubMed ID: 8852526
[TBL] [Abstract][Full Text] [Related]
12. Neutralizing antibodies and the efficacy of interferon beta-1b in relapsing-remitting multiple sclerosis.
Petkau J; White R
Mult Scler; 1997 Dec; 3(6):402. PubMed ID: 9493643
[No Abstract] [Full Text] [Related]
13. Interferon-beta 1b treatment decreases tumor necrosis factor-alpha and increases interleukin-6 production in multiple sclerosis.
Brod SA; Marshall GD; Henninger EM; Sriram S; Khan M; Wolinsky JS
Neurology; 1996 Jun; 46(6):1633-8. PubMed ID: 8649562
[TBL] [Abstract][Full Text] [Related]
14. A meta-analysis of the efficacy and tolerability of interferon-β in multiple sclerosis, overall and by drug and disease type.
Nikfar S; Rahimi R; Abdollahi M
Clin Ther; 2010 Oct; 32(11):1871-88. PubMed ID: 21095482
[TBL] [Abstract][Full Text] [Related]
15. Natural killer cells in relapsing-remitting MS: effect of treatment with interferon beta-1B.
Kastrukoff LF; Morgan NG; Zecchini D; White R; Petkau AJ; Satoh J; Paty DW
Neurology; 1999 Jan; 52(2):351-9. PubMed ID: 9932956
[TBL] [Abstract][Full Text] [Related]
16. Contemporary immunomodulatory therapy for multiple sclerosis.
Rudick RA
J Neuroophthalmol; 2001 Dec; 21(4):284-91. PubMed ID: 11756861
[TBL] [Abstract][Full Text] [Related]
17. Mx proteins in blood leukocytes for monitoring interferon beta-1b therapy in patients with MS.
Kracke A; von Wussow P; Al-Masri AN; Dalley G; Windhagen A; Heidenreich F
Neurology; 2000 Jan; 54(1):193-9. PubMed ID: 10636147
[TBL] [Abstract][Full Text] [Related]
18. Short-term treatment of relapsing remitting multiple sclerosis patients with interferon (IFN)-beta1B transiently increases the blood levels of interleukin (IL)-6, IL-10 and IFN-gamma without significantly modifying those of IL-1beta, IL-2, IL-4 and tumour necrosis factor-alpha.
Nicoletti F; Di Marco R; Patti F; Zaccone P; L'Episcopo MR; Reggio E; Xiang M; Nicoletti A; Reggio A
Cytokine; 2000 Jun; 12(6):682-7. PubMed ID: 10843745
[TBL] [Abstract][Full Text] [Related]
19. Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration.
Khan OA; Xia Q; Bever CT; Johnson KP; Panitch HS; Dhib-Jalbut SS
Neurology; 1996 Jun; 46(6):1639-43. PubMed ID: 8649563
[TBL] [Abstract][Full Text] [Related]
20. RANTES production and expression is reduced in relapsing-remitting multiple sclerosis patients treated with interferon-beta-1b.
Iarlori C; Reale M; Lugaresi A; De Luca G; Bonanni L; Di Iorio A; Feliciani C; Conti P; Gambi D
J Neuroimmunol; 2000 Jul; 107(1):100-7. PubMed ID: 10808056
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
